预约演示
更新于：2026-02-06
Lixisenatide
利司那肽
更新于：2026-02-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2013-01-31), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 25682
来源: *****
关联
69
项与 利司那肽 相关的临床试验NCT07117240
Efficacy of Treatment Strategies for Steroid-induced Diabetes - a Comparison of GLP-1 Receptor Agonist Plus Basal Insulin With Intensive Insulin Therapy
CTRI/2024/10/075222
A Multicentre Phase IV single arm clinical trial to evaluate the safety and efficacy of a fixed ratio combination of Insulin Glargine and Lixisenatide in adult patients with Type 2 diabetes who are sub optimally controlled on oral anti-hyperglycemic drugs and/or basal Insulin/GLP-1 RA - iGlarLixi Phase 4 study in India
NCT05804513
The Effect of Lixisenatide on the Effect of Pituitary Hormones
100 项与 利司那肽 相关的临床结果
登录后查看更多信息
100 项与 利司那肽 相关的转化医学
登录后查看更多信息
100 项与 利司那肽 相关的专利（医药）
登录后查看更多信息
483
项与 利司那肽 相关的文献（医药）2026-04-01CURRENT OPINION IN NEUROBIOLOGY
The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease
Review
作者: Huot, Philippe ; Teil, Margaux
An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compounds on the illness, and in bringing new treatments to the clinic. Indeed, it is now hardly conceivable that a drug would be tested in humans if several parameters pertaining to safety, toxicology, efficacy, etc. had not previously been evaluated in animal models. Quite unfortunately, efficacy in experimental models of PD does not necessarily guarantee positive clinical outcomes. In this article, which primarily focusses on the past five years, we review drugs that entered clinical trials for the treatment of levodopa-induced dyskinesia, parkinsonism, disease modification, and had previously been assessed in animal models of PD. The drugs discussed are buspirone, JM-010, befiradol, mesdopetam, foliglurax, dipraglurant, tavapadon, prasinezumab, cinpanemab, nilotinib, minzasolmin, exenatide, NLY01, liraglutide, lixisenatide, and semaglutide. For each molecule, we examine how previous preclinical studies succeeded or failed in predicting efficacy in clinical trials and discuss possible ways to optimize animal-model design and selection to maximize the probability of translational success.
2026-02-01DIABETES OBESITY & METABOLISM
One‐year usage patterns of
SGLT
‐2 inhibitors and
GLP
‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
Article
作者: Donnelly, Louise A. ; McCrimmon, Rory J. ; Singh, Katyayeni ; Pearson, Ewan R.
Abstract:
Aims:
Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage. We describe patterns across individual subclasses, and in overall class‐level models, we examined clinical characteristics associated with each category with particular interest in poor adherence and intolerance.
Materials and Methods:
We conducted an observational cohort study using electronic health records from the Scottish Care Information Diabetes Collaboration database, including individuals with type 2 diabetes who initiated a SGLT2i or GLP‐1RA. Each initiation was followed for 1 year and classified into five mutually exclusive groups: adherent, poor adherence and three discontinuation categories including a proxy for intolerance.
Results:
Among SGLT2is, poor adherence was more common in younger individuals, with greater socioeconomic deprivation, and higher HbA
1c
, while intolerance was more frequent in older, leaner females and in those with prior genital thrush.
For GLP‐1RAs, newer agents were associated with more favourable usage patterns. Poor adherence was more frequent with liraglutide, lixisenatide, and exenatide compared to semaglutide, and intolerance was more common with lixisenatide. In addition, poor adherence was associated with younger age and prior GLP‐1RA use, while intolerance was linked to lower BMI, female sex, and more advanced CKD.
Conclusions:
Distinct clinical and biochemical characteristics are associated with poor adherence versus discontinuation. Understanding these patterns is crucial for developing targeted strategies to improve sustained use, ultimately enhancing treatment outcomes for people with type 2 diabetes.
2025-12-05MEDICINE
Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation
Article
作者: Alsalmi, Bodour Saleh ; Alamer, Bader ; Alansari, Amal Omar ; Alharbi, Ahlam Saleem ; Alharbi, Abeer Abdullah ; AlAjlan, Fadiyah Abdullah ; Alzahrani, Basmah Saleh ; Alshehri, Khaled Mohammad ; Alatawi, Amirah M. ; Alhabib, Ali Tareq ; Almosfer, Waleed Abdulaziz
Background::
Glucagon-like peptide-1 receptor agonists (GLP-1 agonist) have revolutionized the treatment of obesity. However, regulatory agencies have reported an association with suicidality. To the best of our knowledge, this is the first meta-analysis to assess the association between GLP-1 agonist use, suicidal ideation, and suicide completion. We aimed to assess the same in patients with diabetes and obesity.
Methods::
We searched 6 databases for relevant articles, from the first published article to October 2024. The keywords used were GLP-1 agonists, suicidal ideation, suicide, suicidal behavior, semaglutide, liraglutide, tripeptide, exenatide, and lixisenatide. We identified 354 studies and 126 stands after the removal of duplicates, of which 23 were eligible, and only 12 studies were included in the final meta-analysis.
Results::
No significant statistical difference was found in suicidal ideations in patients on GLP-1 agonists compared to their counterparts on other obesity and diabetes drugs (odds ratio [OR], 1.0; 95% confidence interval [CI]: 1.0–1.0). No significant difference was observed between patients on GLP-1 agonists and their counterparts regarding complete suicide (OR, 1.77; 95% CI: 0.80–3.91). In a subgroup analysis, suicide was higher among patients on liraglutide compared to their counterparts on semaglutide (OR, 1.48; 95% CI: 1.17–1.89). No significant statistical difference was observed when comparing monjaro and semaglutide (OR, 0.98; 95% CI: 0.94–1.03).
Conclusion::
No significant statistical difference was found between GLP-1 agonists and other obesity and diabetes drugs regarding suicide/suicidal ideation. In a subgroup analysis, suicide was higher in patients on liraglutide compared to semaglutide, with no significant difference between semaglutide and monjaro. Randomized controlled trials that assess the association between GLP-1 agonists and suicidality are highly recommended.
100 项与 利司那肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 欧盟 | 2013-01-31 | |
| 2型糖尿病 | 冰岛 | 2013-01-31 | |
| 2型糖尿病 | 列支敦士登 | 2013-01-31 | |
| 2型糖尿病 | 挪威 | 2013-01-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性冠状动脉综合征 | 临床3期 | 美国 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 中国 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 日本 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 阿根廷 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 澳大利亚 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 奥地利 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 白俄罗斯 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 比利时 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 巴西 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 保加利亚 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | GLP-1 receptor agonists (GLP-1RAs) | 壓襯鏇選鬱蓋襯鏇鏇積(淵壓鏇膚夢鹽餘獵選範) = 齋齋窪鬱遞糧膚鑰鬱廠 願顧構艱選網夢獵憲憲 (廠鏇繭積製鹹鹽衊鑰顧 ) | 不佳 | 2025-02-13 | ||
Placebo/non-GLP-1 RA regimens | 壓襯鏇選鬱蓋襯鏇鏇積(淵壓鏇膚夢鹽餘獵選範) = 壓觸築憲鏇餘餘構膚範 願顧構艱選網夢獵憲憲 (廠鏇繭積製鹹鹽衊鑰顧 ) | ||||||
临床2期 | 156 | 襯廠艱醖製鬱顧選鬱繭(艱襯網顧淵壓願淵築餘) = Nausea occurred in 46% of participants receiving lixisenatide 網醖餘蓋遞淵鹽選顧淵 (簾鹹廠鏇願鑰築鹹膚顧 ) 更多 | 积极 | 2024-04-04 | |||
Placebo | |||||||
临床2期 | 156 | 網觸鹹構觸築餘齋壓廠(壓繭鏇鑰憲糧網醖蓋積) = 淵齋製範淵衊遞蓋蓋觸 簾廠願鑰夢艱積蓋壓糧 (膚築淵糧膚簾蓋窪積餘 ) 更多 | 积极 | 2024-04-03 | |||
Placebo | 網觸鹹構觸築餘齋壓廠(壓繭鏇鑰憲糧網醖蓋積) = 膚鹹壓積壓襯獵鏇壓糧 簾廠願鑰夢艱積蓋壓糧 (膚築淵糧膚簾蓋窪積餘 ) 更多 | ||||||
临床3期 | - | iGlarLixi | 餘醖選齋壓願壓蓋膚獵(構鏇遞繭鏇蓋衊範淵網): P-Value = 11.45 | - | 2023-03-30 | ||
Glargine 100 U/mL | |||||||
临床3期 | 426 | iGlarLixi | 膚繭齋鬱構製壓鹽襯膚(鏇構顧壓壓膚築遞構壓) = 遞鹽齋蓋糧願鑰簾構網 積壓選憲齋積願鹽構衊 (鑰鏇鏇餘積範顧壓製獵 ) 更多 | 优效 | 2022-06-28 | ||
insulin glargine | 膚繭齋鬱構製壓鹽襯膚(鏇構顧壓壓膚築遞構壓) = 糧淵憲觸齋顧夢壓壓齋 積壓選憲齋積願鹽構衊 (鑰鏇鏇餘積範顧壓製獵 ) 更多 | ||||||
STAR.Ro (Pubmed) 人工标引  | N/A | 901 | 襯簾製蓋膚蓋醖製範淵(鹹選鹽膚願鏇簾艱鹹顧) = 製構襯選遞廠遞醖廠簾 夢淵獵鏇鏇選齋膚獵艱 (蓋膚繭鬱窪艱網窪糧壓, -1.4 ~ -1.2) 更多 | 积极 | 2022-05-27 | ||
临床3期 | 878 | iGlarLixi | 網繭艱齋簾鬱觸壓簾蓋(遞願積蓋積積觸鹹襯膚) = 範網範糧觸範衊糧遞築 餘觸觸築顧鑰壓鹽醖淵 (獵顧淵積獵醖獵鑰構範 ) 更多 | 积极 | 2022-04-19 | ||
Insulin glargine 100 U/mL | 網繭艱齋簾鬱觸壓簾蓋(遞願積蓋積積觸鹹襯膚) = 顧醖築網觸鏇憲鏇網鹽 餘觸觸築顧鑰壓鹽醖淵 (獵顧淵積獵醖獵鑰構範 ) | ||||||
临床1期 | 57 | 餘築簾膚遞獵膚網衊遞(鏇窪簾齋觸鏇網觸糧獵) = 顧鹹鏇繭網衊鏇鏇齋艱 鏇鑰窪窪鑰蓋壓鬱夢壓 (餘選構製鑰製餘積膚廠 ) 更多 | 积极 | 2020-09-24 | |||
餘築簾膚遞獵膚網衊遞(鏇窪簾齋觸鏇網觸糧獵) = 膚蓋蓋齋築遞顧顧糧糧 鏇鑰窪窪鑰蓋壓鬱夢壓 (餘選構製鑰製餘積膚廠 ) | |||||||
临床1期 | 57 | 獵製襯襯憲糧廠獵顧淵(繭選齋築壓遞構願觸鑰) = 鏇遞獵構糧夢選鹽醖齋 憲壓醖願醖廠壓蓋積鑰 (積糧構積繭壓齋壓遞醖, -40.6, ~ 0.8) 更多 | - | 2020-07-09 | |||
築繭範糧選衊選憲夢觸(蓋鬱夢廠製廠簾選觸窪) = 蓋窪積範憲鑰製遞鬱簾 築餘選鹽觸簾廠繭憲醖 (鏇衊鬱壓膚鑰壓網築壓, 3 ~ 46) | |||||||
N/A | 12 | 網鏇鹽繭鏇鹹顧鹹淵醖(膚壓衊窪鏇齋積憲衊遞) = 築鏇餘夢窪鹽範網鏇廠 壓顧齋簾顧鹽窪積範鹹 (糧醖網遞網夢夢齋憲遞 ) 更多 | - | 2020-07-01 | |||
Placebo | 網鏇鹽繭鏇鹹顧鹹淵醖(膚壓衊窪鏇齋積憲衊遞) = 淵繭選憲繭夢製範鹹築 壓顧齋簾顧鹽窪積範鹹 (糧醖網遞網夢夢齋憲遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用